𝛼SK or Search

ENTITY

TransThera Sciences (Nanjing) (2617 HK)

43

Analysis

Health Care • China

TransThera Sciences (Nanjing) Inc. is a China-based biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. Its core product, Tinengotinib (TT-00420), is a multi-targeted kinase (MTK) inhibitor in clinical stages for treating relapsed or refractory, drug-resistant solid tumors. The company is headquartered in Nanjing, China, and was founded in 2014.

more

Refresh

Exchange Announcement • 21 Sep 2026 20:07

Interim Report 2026

Exchange Announcement • 18 Sep 2026 18:50

Voluntary Announcement First Patient Dosed In Phase Ii Clinical Trial Of Tinengotinib In Combination With Novel Hormonal Therapy For Pretreated And Progressed Metastatic Castration-Resistant Prostate Cancer In China

Exchange Announcement • 18 Sep 2026 18:44

Voluntary Announcement Inclusion Of Yochanra (Tinengotinib) In The Csco Guidelines For The Diagnosis And Treatment Of Biliary Tract Cancers (2026)

Exchange Announcement • 26 Aug 2026 18:22

Interim Results Announcement For The Six Months Ended 30 June 2026

Exchange Announcement • 14 Aug 2026 16:57

Date Of Board Meeting

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x